Indian Firms Push For Favorable USTR IPR Review
Executive Summary
It’s that time of the year when Indian and US firms lock horns around all things IPR [intellectual property rights] ahead of the USTR’s annual Special 301 report. Indian pharma firms want India off the USTR’s Priority Watch List, while PhRMA says it remains concerned about the challenging policy environment and weak patent enforcement in India.
You may also be interested in...
Abbott Exits Indian Industry Group: Fault Lines Showing?
Abbott’s unexpected decision to move out of the Organization of Pharmaceutical Producers of India (OPPI), the premier multinational industry body in India, has provided enough grist to the rumor mill to work overtime. Experts tell Scrip where the divisive issues may lie.
Can Pharmas Come Out Unscathed As China-US Trade War Escalates?
As a simmering trade dispute between the US and China looks set to continue worsening, many companies in the pharma sector are closely watching what's coming and getting ready for any disruption. But what is the actual and predicted impact on exporters and producers in China, India and the US?
Can Pharmas Come Out Unscathed As China-US Trade War Escalates?
As a simmering trade dispute between the US and China looks set to continue worsening, many companies in the pharma sector are closely watching what's coming and getting ready for any disruption. But what is the actual and predicted impact on exporters and producers in China, India and the US?